VanEck非必需消费品TruSector主动型ETF TRUD 深 沪
等待开盘 10-14 09:30:00 美东时间
25.3992
+0.008
+0.03%
华盛通- 最 高25.51
- 今 开25.48
- 成交量 1.39万股
- 最 低 25.36
- 昨 收 25.3913
- 总市值 8280.14万
- 52周最高 27.4027
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 22.7622
- 委 比 0.00%
- 总股本 326.00万
- 历史最高 27.3822
- 量 比 0.45
- 振 幅 0.59%
- 历史最低 22.7622
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Merck secures Japanese approval for subcutaneous Keytruda
Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all indications currently approved for Keytr...
09-21 20:17
美股夜盘 | VanEck非必需消费品TruSector主动型ETF跌11.69%，最新股价22.72美元
VanEck非必需消费品TruSector主动型ETF跌11.69%，报22.72美元
09-08 09:42
Merck Stock Jumps on Phase 3 Cancer Vaccine Win as Keytruda Risk Eases
TradingKey - Merck stock surged after its personalized mRNA cancer therapy met both Phase 3 melanoma endpoints. Strong Q2 sales and pipeline growth support MRK’s outlook.
08-20 02:27
Amazon earnings preview: Will AWS reacceleration justify the capex binge?
Amazon (AMZN) is lined up to report second quarter earnings on July 30 after the market closes. Investors will be looking for proof that AWS growth is reaccelerating, retail margins are holding up, an...
07-25 19:05
VanEck推出四只新ETF，TruSector系列实现GICS全行业覆盖
资产管理公司VanEck推出四只新的TruSector系列ETF，分别为能源（TRUN）、公用事业（TRUU）、房地产（TRUR）和材料（TRUM）板块基金...
07-08 22:34
Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's
06-09 04:31
FDA Approves Agilent Technologies' Expanded Use Of PD-L1 IHC 22C3 pharmDx, Code GE006,
Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,²
06-03 04:17
